pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ABBVIE · news · pharmadog
← back to ABBVIE
News mentioning ABBVIE
229
stories
Sep 17, 26
North Immunology joins biotech reverse merger boom with Aethlon deal
biopharma dive
Sep 17, 26
North Immunology goes public via reverse merger as eczema drug heads toward clinic
fiercebiotech
Sep 17, 26
Trending: Top biopharma disciplines with jobs live now
biospace
Sep 17, 26
Biopharma hiring hotspots: States, disciplines where demand is highest
biospace
Sep 16, 26
Deep dive: Psychedelics back on FDA’s doorstep
biospace
Sep 16, 26
Novartis ends ALS program after phase 2 flop, adding to R&D woes
fiercebiotech
Sep 15, 26
GSK doubles down on Chimagen with $750M multiple myeloma wager
fiercebiotech
Sep 14, 26
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
fiercebiotech
Sep 14, 26
Psychedelic therapies ride wave of public favor into FDA hearing
biospace
Sep 11, 26
Yarrow brings in more cash; AbbVie drug succeeds in menstrual migraine trial
endpoints
Sep 11, 26
Frazier adds $1.1B+ to small and mid-sized biotech fund
biospace
Sep 10, 26
Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'
biospace
Sep 9, 26
Beyond China: Five other overseas destinations for biopharma dollars
biospace
Sep 8, 26
Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
fiercebiotech
Sep 8, 26
Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint
fiercebiotech
Sep 6, 26
AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies
fiercebiotech
Sep 5, 26
AbbVie-allied ADARx aims for IPO with three drugs in the clinic
endpoints
Sep 4, 26
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
biopharma dive
Sep 4, 26
This week in charts: China deals, stock flatlines and Lilly’s M&A spree
biopharma dive
Sep 4, 26
Biotech is back, with H1 progress smoothing glide path through end of year: Truist
biospace
Sep 4, 26
AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
biospace
Sep 3, 26
AbbVie claims Phase 3 win for multiple myeloma drug etentamig
endpoints
Sep 3, 26
Psilocybin proves promising in neuropathic pain mouse study
fiercebiotech
Sep 3, 26
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
fiercebiotech
Sep 3, 26
Recon: CBER official overruled Replimune melanoma drug rejection; AbbVie claims Phase 3 win for multiple myeloma drug
raps
Sep 1, 26
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
fiercebiotech
Aug 31, 26
BMS’ neuro renaissance was built on back of Celgene mega-merger
biospace
Aug 28, 26
FDA green lights Priovant drug for rare skin disease
biopharma dive
Aug 27, 26
Chutes & Ladders—Vivace revs up C-suite ahead of pivotal push
fiercebiotech
Aug 27, 26
Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
biospace
← prev
page 5 of 8
next →